Genzyme's Alemtuzumab Shows Sustained Reduction in Relapses and Disability
- Details
- Category: Genzyme
Genzyme Corporation (Nasdaq: GENZ) reported five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial. This sub-group analysis found that nearly 90 percent of alemtuzumab-treated patients were free of sustained accumulation of disability, and that patients receiving alemtuzumab also maintained improved mean disability scores and a low risk of relapse over the 60-month follow-up period.
Lundbeck and Genmab enter into a research collaboration
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) announced an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with Genmab A/S (Genmab). Following the agreement, Genmab will create novel human antibodies to a defined number of targets identified by Lundbeck.
Novartis affirms commitment to sustain efforts toward final elimination of leprosy
- Details
- Category: Novartis
At a ceremony at the WHO's headquarters in Geneva, Joseph Jimenez, CEO of Novartis, and Dr Margaret Chan, Director-General of the WHO, signed a Memorandum of Understanding (MoU) to continue their collaboration toward a world free of leprosy.
Pfizer to Acquire King Pharmaceuticals, Inc.
- Details
- Category: Pfizer
Pfizer Inc.(NYSE: PFE) and King Pharmaceuticals, Inc. (NYSE: KG) have entered into a definitive merger agreement. Under the terms of the agreement, Pfizer will acquire King, a diversified specialty pharmaceutical discovery and clinical development company, for $3.6 billion in cash, or $14.25 per share, which represents a premium of approximately 40% to King's closing price as of October 11, 2010, and 46% percent to the one-month average closing price as of the same date.
Lundbeck and Merck sign exclusive commercialisation agreement for SYCREST®
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) and Merck & Co. (Merck), also known outside the United States and Canada as MSD, today announced a commercialisation agreement for SYCREST® (asenapine) sublingual tablets (5 mg, 10 mg).
Afatinib (BIBW 2992) triples progression free survival in phase III study in lung cancer patients
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced promising results from two clinical trials of its investigational cancer compound afatinib (BIBW 2992) presented at the 35 th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.
Denosumab Delays the Onset of Bone Complications Compared to Zometa
- Details
- Category: Amgen
Amgen (Nasdaq:AMGN) announced results from two integrated analyses of head-to-head pivotal Phase 3 trials comparing denosumab to Zometa(R) (zoledronic acid), the current standard of care in the prevention of skeletal related events (SREs) in patients with advanced malignancies involving bone.
More Pharma News ...
- Abbott Named One of the 'Top Employers' in the Biotech and Pharmaceutical Industry by Science Magazine
- Genzyme Board Unanimously Rejects Sanofi-Aventis Tender Offer
- Bayer's Xarelto® Recognised with 2010 International Prix Galien Award
- Convergence Pharmaceuticals Successfully Launched out of GSK to Focus on Novel High Value Analgesics
- Novartis discontinues development of two investigational compounds
- Lundbeck enters into license agreement with Kyowa Hakko Kirin for A2a antagonists
- Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme